The present invention relates to the amplification of nucleic acids and has particular (but not necessarily exclusive) application to the production of amplified amounts of a particular target sequence for detection for the purposes of medical diagnosis procedures.
Many medical conditions are characterised by the presence (in the patient's body) of a nucleic acid having a particular nucleotide sequence. The nucleic acid sequence may, for example, be one present in a pathogenic bacteria, virus or other microorganism which has “invaded” the patient's body and which is responsible for an illness in the patient. In many such instances, the presence of the microorganism in the patient's body may be diagnosed by analysing a sample such as tissue, blood, urine, sputum etc from a patient for the presence (in the sample) of a nucleic acid sequence that characterises the microorganism. However, in many cases, the amount of the characterising nucleic acid sequence in the sample is very low and below detectable limits. As such, amplification procedures are employed to enhance the amount of the characteristic sequence (or a characteristic variant thereof, e.g. a DNA sequence derived from a characterising rRNA sequence) for the purposes of detection.
According to a first aspect of the present invention there is provided a method of amplifying a nucleic acid sequence comprising:
The amplification method of the first aspect of the present invention is based on a combination of a number of features. In particular, the method utilises an inter-related combination of (a) a first nucleic acid primer having a digestion resistant region remote from its 5′-end, and (b) a double stranded nucleic acid comprising first and second nucleic acid strands hybridised to each other, the first strand incorporating the nucleic acid sequence to be amplified. The combination is such that the first nucleic acid strand has, extending from its 5′-end, a 5′-end region with the same nucleotide sequence as the first primer including the digestion resistant sequence.
In the amplification method, the exonuclease digests the 5′-end region of the first strand to, but not through, the digestion resistant region in the 5′-end region of the strand. As a result, the 3′-end of the second strand is exposed and provides a site for hybridisation of the first primer which, in hybridising to the 3′-end of the second strand, displaces the undigested portion of the 5′-end region of the first strand. The first primer is then extended by the action of the strand displacing polymerase to produce a copy of the first strand. The 5′-end region of the newly synthesised first strand can then be digested (by the exonuclease) and the described process in effect repeats itself.
The amplification method of the invention is preferably one conducted under isothermal conditions, e.g. at a temperature of 45° C. to 55° C. As such, the strand displacing polymerase is one capable of copying a template strand under isothermal conditions. Similarly, the exonuclease is one capable of effecting digestion under the preferred isothermal conditions. Preferred strand displacement polymerases for use in the invention are those that lack 3′ exonuclease activity. The strand displacing polymerase may be one of the Bst series, although there are other possibilities as discussed below. The exonuclease is preferably one that recognises a blunt end of a double stranded nucleic acid molecule. It is particularly preferred that the exonuclease is A-exonuclease which progressively degrades one strand of double stranded DNA in the 5′ and 3′ direction in the following order of preference for the configuration of the ends of the double stranded structure namely 5′-recessed>blunt<<5′-overhang with a 10× preference for phosphorylated rather than hydroxylated ends.
In one embodiment of the invention, the second strand of the double stranded nucleic acid molecule may be “normal” in that it does not have a digestion resistant region. A process in accordance with this embodiment is described below in more detail with reference to
In a further embodiment of the invention, the method utilises a second nucleic acid primer having (like the first primer) a digestion resistant region remote from its 5′-end. Furthermore, in this embodiment the second strand has a 5′-end region extending from its 5′-end with the same nucleotide sequence as the second primer (including the digestion resistant sequence). This embodiment is described below in more detail with reference to
For all embodiments of the invention, the double stranded DNA molecule containing the sequence(s) to be amplified may be synthesised from a naturally occurring nucleic acid strand containing a sequence of interest. The naturally occurring strand may, for example, be one present in a bacteria or virus. The naturally occurring strand may, for example, be an rRNA strand. A procedure for obtaining a double stranded nucleic acid construct for use in the method of the invention from an rRNA strand is described below with reference to
For all embodiments of the invention, it is preferred that the first primer (and also the second primer, if utilised) comprises 20 to 30 nucleotides. Correspondingly, the 5′-end region of the first strand (and, if utilised, the 5′-end region of the second strand) has a length of 20 to 30 nucleotides.
The digestion resistant region of the first primer (and second primer, if utilised) is preferably provided approximately mid-way along the length of the primer. Thus, in the case that the primer comprises 20 nucleotides, the digestion resistant region preferably starts about 8-10 nucleotides from 5′-end of the primer. In the case where the primer comprises 30 nucleotides the digestion resistant region preferably starts about 13 to 15 nucleotides from the 5′ end.
The digestion resistant regions may be provided by at least one nucleotide that is resistant to digestion by the exonuclease. Preferably the digestion resistant region comprises a consecutive sequence of a plurality (e.g. 3 to 6) of the modified nucleotides. The modified nucleotides may for example be phosphorothioate nucleotides (i.e. nucleotides in which a non-bridging oxygen atom is replaced by sulphur).
As indicated, it is preferred that the digestion resistant region (e.g. comprising a consecutive sequence of 3 to 6 modified nucleotides) is present approximately mid-way along the 1′ primer (and also 2′ if utilised). In such cases, it is particularly preferred that the strand displacement polymerase is one that lacks 3′ exonuclease activity. We do not however preclude the possibility that the digestion resistant region extends to the 3′ end or the primer in which case the use of a strand-displacing polymerase with 3′ exonuclease activity (e.g. phi29) may be employed.
Amplified sequences produced in accordance with the method of the invention may, for example, have a length of 50 to 150 bases per strand.
The method of the invention may further comprise the step of detecting the amplified sequence. In a preferred embodiment of the invention, detection is effected by the steps of:
In step 2(ii) of this detection method, the product mixture is subjected successively to denaturation and then re-hybridisation conditions. Under the denaturation conditions, the reporter strand and quencher strand are separate strands within the product mixture. Under the re-hybridisation conditions, the reporter strand is able to hybridise to the amplified nucleic acid sequence, rather than to the quencher strand. Thus fluorescence after the re-hybridisation step confirms the presence of the amplified sequence. Generally, the quencher strand will be present in a molar excess as compared to the reporter strand. The molar ratio of quencher strand to reporter strand may, for example (1.3-1.5); 1. Embodiments of this detection method are described more fully below in conjunction with
The method of the invention is applicable particularly, but by no means exclusively, to confirming the presence of a particular target nucleic acid sequence in a biological sample, for example tissue, blood, urine, sputum etc. The target nucleic acid may, for example, be one present in a pathogenic bacteria which is present in the tissue sample and which is responsible for illness of the patient. As outlined above, and as described in more detail below rRNA extracted from the sample may be used to prepare cDNA comprising first and second nucleic acid strands, hybridised to each other, said first strand incorporating a first nucleic acid sequence confirmatory of the presence of target nucleic acid sequence in the biological sample and having a first 5′-end region which remote from its 5′-end has a nucleotide sequence resistant to digestion. The cDNA may then be amplified using the procedures described more fully above.
This leads to a second aspect of the invention, according to which there is provided a method of determining the presence or otherwise of target nucleic acid sequence in a biological sample, the method comprising the steps of:
All features of the first aspect of the invention as described above are applicable mutatis mutandis to the method of the second aspect of the invention.
The derivative sample may, for example, comprise cDNA prepared from rRNA extracted from the biological sample.
The invention will be further described, by way of example only, with reference to the accompanying drawings, in which:
Reference is firstly made to
As shown in
Turning now to antisense strand 3, this is a “plain” strand in that it does not have a digestion resistant region. Additionally, the 5′-end of antisense strand 3 is hydroxylated (rather than phosphorylated as in the case of sense strand 2).
Reference is now made to
To perform the method of
In the initial step of the reaction, the λ-exonuclease digests the 5′-end region 4 of sense strand 2 up to (but not beyond) the digestion resistant region 6. This is due to the “ability” of λ-exonuclease to digest one strand of double stranded DNA in the 5′-3′ direction in the following order of preference for the configuration of the ends of the double stranded structure, namely 5′-recessed>blunt<<5′-overhang with a 10× preference for phosphorylated rather than hydroxylated ends. However, the A-exonuclease is not able to effect degradation of sense strand 2 through digestion resistant region 6 thereof. For convenience, the partially digested sense strand is represented by reference numeral 2d. This digestion renders the antisense strand 3 single stranded from its 3′-end over the region to which the now-digested portion of sense strand 2 was previously hybridised. This is clearly depicted in step (ii) of
The liberated 3′-end region of antisense strand 3 forms an overhang 12 which provides a target for hybridisation of primer 10 (see step (iii) of
It will be appreciated that (since primer 10 has exactly the same sequence (and length) as end region 4 of the sense strand 2 shown in step (i) of
For the purposes of simplicity,
It is also possible that since the target molecule is no longer fully double stranded the recess 5′-end strand will dissociate from the antisense strand which will liberate an antisense sequence of greater length that the originally λ-exonuclease/liberated sequence. Although this cannot be proven, it can be presumed considering that the enzyme target is not fully double stranded and the reaction of the method of the invention may take place at relatively elevated temperatures (e.g. 45 to 55° C.) that in theory could induce further dissociation.
Reference is now made to
Sense strand 102 is similar to sense strand 2 (of nucleic acid molecule 1) in that it has a 5′-end region 104 that extends from a phosphorylated 5′-end of sense strand 102 to a point depicted by line 105. Intermediate its ends (and approximately halfway therealong) the 5′-end region 104 has a digestion resistant region 106 formed of modified oligonucleotides, e.g. phosphorothioate nucleotides.
Nucleic acid molecule 101 is distinguished from nucleic acid molecule 1 in that (as depicted in
The reaction of
In order to effect the reaction of
In the next step of the method, primer 110 hybridises to overhang 112 and primer 111 hybridises to overhang 113. Extension of the hybridised primers 110 and 111 by the strand digesting polymerase leads to the production of the two double stranded molecules referenced as 114 and 115. The double stranded product 114 comprises the residue 102d of sense strand 102 hybridised to a new strand 116 generated by extension of primer 111. The product of Box 6 comprises the residue 103d of antisense strand 103 hybridised to a new strand 117 generated from primer 110.
Further processing of double stranded nucleic acid molecule 114 is shown in
Referring firstly to
Primer 111 is now extended with concomitant displacement of strand 116d. There are two products of this stage. One is the double stranded molecule 114 (produced by extension of primer 111 using strand 102d as a template). This double stranded molecule is now effectively recycled in the process of
Strand 121 of double stranded molecule 120 then undergoes digestion (by the action of λ-exonuclease) from its 5′-end up to (but not beyond) the digestion resistant region 106 to provide strand 121d and expose the 3′-end of strand 122 as an overhang 123. As depicted in
Reference is now made to
Thus, strand 117 undergoes digestion by the λ-exonuclease from its 5′-end to yield a partially digested strand which is identical to strand 121d described above in relation to
Primer 110 is now extended with concomitant displacement of strand 121d. There are two products of this stage. One is the double stranded molecule 115 (produced by extension of primer 110 using strand 103d as a template). This double stranded molecule is now effectively recycled in the process of
Strand 133 of double stranded molecule 132 then undergoes digestion (by the action of λ-exonuclease) from its 5′-end up to (but not beyond) the digestion resistant region 109 to provide a partially digested strand which is identical to strand 116d produced in
It will be appreciated from the foregoing description that the procedure of
The overall procedure described with reference to
Reference is now made to
In the method, primer 111 hybridises to RNA strand 301 and the RT enzyme synthesizes complementary DNA (cDNA) 302 by extension of primer 111 (see Boxes 2 and 3 of
It is unlikely that the released cDNA strand will play a further role in the LEA reaction because even though a primer, such as 110, will hybridise and polymerise it will not produce a blunt end on its 5′-end because it will be recessed (long cDNA template 3′-end overhang).
Reference is now made to
The two reverse primers 351 and 352 (dotted, and long dashed and dotted line) hybridize to strand 350 and polymerise to produce synthetic strands 354 and 355 respectively (dotted, and long dashed and dotted line). The synthetic strand 355 (long dashed and dotted line) displaces synthetic strand 354 (dotted line), providing in this way a template for primer 353 (medium dashed line) to be extended to produce synthetic strand 356 which thereby produces a double stranded molecule 357. This double stranded molecule 357 will be the target for λ-exonuclease which will digest the nuclease-sensitive part of the synthetic strand 354 (dotted line). This will liberate the sequence on the 3′ end of the template strand 356 (medium dashed line) will allow the primer 351 (dotted line) to hybridise and polymerise creating an amplicon as in the final step of
Reference is now made to
In
As shown in
As shown in
The reporter construct 404 is added to the product of the amplification reaction and the mixture raised to elevated temperature (e.g. boiling point) to denature both the double stranded amplicons 401 and the double stranded reporter constructs 404. The mixture is then allowed to cool (e.g. to room temperature) so that sequences 405 are able to hybridise to sequences 402 whereas sequences 406 can hybridise to sequences 403. It will be appreciated that in the double stranded constructs comprising sequence 405 hybridised to sequence 402 the Cy5 is no longer quenched and is therefore capable of providing a fluorescent signal to confirm the presence of the amplified product. It will be appreciated that other hybridisation products are possible (e.g. sequences 402 and 403 may re-hybridise together, similarity sequences 405 and 406) but it is the hybridisation of sequences 402 and 405 that are important for the purposes of detection.
An advantage of the detection procedure shown in
The invention will be illustrated by the following non-limiting Examples.
This Example demonstrates detection of Neisseria gonorrhoeae (NG) using procedures in accordance with the present invention. More particularly, the Example demonstrates production of a double stranded DNA molecule from an rRNA extract of NG cells using a procedure in accordance with
The double stranded DNA molecule (produced from rRNA extracted from NG) is shown in
Table 1 shows the oligonucleotide sequences used in this Example. By way of explanation, the “forward primer” sequence corresponds with primer 110 in
For the purposes of this Example, rRNA was extracted from 100×106 NG cells (determined by total viable count (TVC)) using the procedure described in UK Patent Appln. No. 1609115.9 to give 200 microLt eluate (Elution Buffer (EB):10 mM Tris-HCl, pH9.0, 0.5 mM EDTA). The same procedure was used to obtain a 200 microLt eluate of 100×106 EC cells (determined by optical density (od) measurements).
For the purposes of this Example, it is assumed that all rRNA from both the NG and EC cells is collected in the eluate (i.e. 100% extraction efficiency).
RNA derived from 1×106 EC cells was mixed with RNA derived from 250, 500, 1000 and 2000 NG cells and the volume was made up to 100 microLt. In detail, 2 microLt of the 200 microLt eluate extracted from 100×106 EC cells will contain RNA derived from 1×106 EC cells (on the basis of the above assumption, i.e. 100% extraction efficiency). 2 microLt aliquots of the EC eluate were mixed separately with 2 microLt aliquots of a 1/4000, 1/2000, 1/1000 and 1/500 dilutions of the 200 microLt eluate of the NG RNA (the dilutions containing RNA from 250, 500, 1000 and 2000 NG cells respectively, extracted from 100×106 of NG cells starting material, again assuming 100% extraction efficiency). The final volume was made up at 100 microLt in H2O, containing final concentrations of 50 microM for each of the two primers (FW and RV), 0.2 mM dNTPs, 4 mM MgSO4, 20 mM Tris-HCl, 10 mM (NH4)2SO4, 150 mM KCl, 0.1% Tween 20, pH8.8 at 25° C. plus 0.3 microLt (4.5 U) of Warm Start Reverse Transcriptase (New England Biolabs, M0380).
Two negative control conditions were included one with 2 microLt of EB and one condition with only 2 microLt of EC RNA (1×106 EC background control). Each condition was in triplicate.
The samples were left at 48° C. for 10 mins after which 5 microLt of an enzyme mixture: [1 microLt (8 U) BST 3.0 DNA polymerase (New England Biolabs, M0374) plus 0.3 microLt (1.5 U) λ-exonuclease (New England Biolabs, M0262) plus 3.7 microLt of H2O] was added to each sample and the final mix was left again to incubate at 48° C. for 10 mins.
After the end of this incubation a 10 microLt Assay mix: [Reporter oligo (1 microLt, 10 pmol) plus Quencher oligo (1.4 microLt, 14 pmol) made up at 10 microLt in H2O containing 15.2 mM Tris-HCl, 7.6 mM (NH4)2SO4, 114 mM KCl, 0.076% Tween 20, pH8.8 at 25° C.] was added to each replicate. The final mix was incubated at 95° C. for 5 mins, then left at room temperature for 2 mins, transferred to black polycarbonate wells and relative fluorescence units (RFU) measurements were taken on a fluorescent plate reader 3× times for each sample.
Values for the 3 reads were averaged for each replicate and these read averages were used for statistical analysis. This experiment was conducted independently 9 times. A one way analysis of variance was conducted using one way ANOVA with post-hoc analysis of variance using an unpaired Student's t-test. NG specific signal vs the non-specific 106 EC signal is significant for all NG titration points (***p≤0.001). Data points are the means of 9 separate experiments conducted in triplicate ±SEM (
This Example provides a comparison of the amplification method of the present invention with PCR.
A 200 microLt eluate comprising rRNA extracted from 100×106 NG cells was prepared as described in Example 1.
(10 microLt of the extract corresponding to 5 million NG cells (assuming 100% extraction efficiency) was treated with 2 U of DNase I (New England Biolabs, #M0303) in 1× DNase I buffer (10 mM Tris-HCl, 2.5 mM MgCl2, 0.5 mM CaCl2, pH 7.6 @ 25° C.) for 30 minutes at 37° C. and the enzyme was denatured at 75° C. for 10 minutes. This was to ensure that no trace of DNA was present in the RNA extract that could affect the PCR result (PCR could amplify the 16S gene as well as cDNA made from 16S rRNA)
Again assuming 100% extraction efficiency, aliquots of the DNase I-treated RNA extract were diluted with water to produce samples representing 1000000, 200000, 100000, 50000 and 25000 NG cells. These samples were then made up to a final volume of 100 microLt in H2O, containing final concentrations of 50 microM for each of the two primers (FW and RV—see Table 1), 0.2 mM dNTPs, 4 mM MgSO4, 20 mM Tris-HCl, 10 mM (NH4)2SO4, 150 mM KCl, 0.1% Tween 20, pH8.8 at 25° C. plus 0.3 microLt (4.5 U) of Warm Start Reverse Transcriptase (New England Biolabs, M0380). A negative background fluorescent control sample was prepared in a similar manner from 1 microLt of the elution buffer (EB) used for the RNA extraction procedure.
1 microLt aliquots of each cDNA-containing samples and also the EB were used, as described below, for the purposes of (a) amplification reactions in accordance with the invention, and (b) amplification by PCR.
For the amplification procedure in accordance with the invention, the 1 microLt aliquots were made-up to 100 microLt final volume in H2O containing: final concentrations of 1.2 microM for each of the two primers (FW and RV), 0.2 mM dNTPs, 4 mM MgSO4, 20 mM Tris-HCl, 10 mM (NH4)2SO4, 150 mM KCl, 0.1% Tween 20, pH8.8 at 25° C., 8 U BST 3.0 DNA polymerase plus 1.5 U λ-exonuclease. The thus prepared samples therefore represented 10000, 20000, 1000, 500 and 250 NG cells. All samples were prepared (and tested) in duplicate. The amplification reaction was effected at 48° C. for 10 minutes and the product mixture was left on ice until assaying.
For the PCR reaction, the 1 microLt cDNA-containing samples (or the EB control) were diluted to 100 microLt final volume in H2O containing: 10 mM Tris-HCl, 50 mM KCl, 1.5 mM, MgCl2, pH 8.3 @ 25° C., 2.5 U Taq Polymerase (New England Biolabs, #0273), 1.2 microM for each of the two primers (FW and RV), and 0.2 mM dNTPs. The PCR amplification protocol was effected using 13 cycles each consisting of denaturation at 95° C., annealing at 57° C. and polymerization at 68° C., with 30 seconds for each temperature (recorded total time of 33 minutes). The product mixture was left on ice until assaying.
The product mixtures obtained (a) using the amplification method of the invention, and (b) amplification by PCR were assayed in the same manner described above in Example 1. The results are shown in
The results in
This Example demonstrates the effect of buffer on the amplification yield.
Using the procedure described in Example 1, an RNA extract was prepared from a pellet of extract (starting material a pellet of 100×106 Neisseria gonorrhoeae (NG) lab grown cells eluted using the same elution buffer (EB) as used in Example 1 (pH9).
2 microLt aliquots eluate dilutions dilution in EB corresponding to a total of 1000 NG cells or 2 microLt of EB were added to 81.3 microLt of either H2O or EB or 10 mM Tris-HCl pH8, 0.5 mM EDTA (“EB pH8”) in duplicate (the rest of the volume to make up to 100 microLt was H2O with reverse transcription enzyme, and LEA constituents including Tris-HCl in a concentrated format that when diluted to a final volume of 100 microLt was at 20 mM providing a pH 8.8 value.
(Therefore, with the addition of 81.3 microLt of EB or “EB pH8” an extra 8.13 mM of Tris-HCl was added to the reaction making a final concentration of Tris-HCl at 28.13 mM). Reverse transcription, amplification and assaying were carried as in Example 1 (using 4.5 U of the Warm Start Reverse Transcriptase, 8 U of the BST 3.0 DNA polymerase, and 1.5 U of the λ-exonuclease).
The results are shown in
In
In
Number | Date | Country | Kind |
---|---|---|---|
1617491.4 | Oct 2016 | GB | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/GB2017/053128 | 10/16/2017 | WO | 00 |